Puma Biotechnology (NASDAQ:PBYI) Releases Earnings Results, Beats Estimates By $0.06 EPS

Puma Biotechnology (NASDAQ:PBYI) issued its earnings results on Thursday. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.09 by $0.06, FiscalAI reports. The firm had revenue of $55.10 million during the quarter, compared to analysts’ expectations of $57.50 million. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%.

Here are the key takeaways from Puma Biotechnology’s conference call:

• Q3 revenue was $55.1 million, with net product revenue of $54.1 million, up from $53.6 million in Q2. However, U.S. NERLYNX net sales fell to $50.6 million from $53.6 million, while $3.6 million of product-supply revenue came from international partners.
• NERLYNX demand was mixed: U.S. demand rose 5% year over year but fell 3% quarter over quarter, while new patient starts declined 9% year over year and 13% sequentially. The company also lowered its 2026 product-revenue outlook slightly and cut its royalty forecast to $18–$19 million from $20–$23 million, citing a China royalty-rate reduction after generic market share crossed a threshold.
• Puma raised its full-year 2026 net-income outlook to $20–$22 million from $17–$20 million and expects $10–$12 million in Q4 net income. It ended Q3 with $108.5 million in cash, cash equivalents, and marketable securities and is now debt-free.
• Puma said preliminary ALISCA-Breast1 data supports considering a Phase III alisertib trial; updated interim results are expected at the San Antonio Breast Cancer Symposium in December, with discussions with regulators planned for the first half of 2027. The company also expects additional ALISCA-Lung1 interim data and initial ALISCA-Lung2 data in 2027, though these remain investigational programs.

Puma Biotechnology Price Performance

Shares of Puma Biotechnology stock traded down $1.52 during midday trading on Friday, hitting $8.25. 1,279,729 shares of the company were exchanged, compared to its average volume of 359,117. The firm has a market cap of $425.87 million, a P/E ratio of 17.94 and a beta of 1.40. Puma Biotechnology has a 52 week low of $4.57 and a 52 week high of $11.50. The firm has a 50 day simple moving average of $9.88 and a 200-day simple moving average of $7.99.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PBYI shares. Weiss Ratings raised shares of Puma Biotechnology from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. TD Cowen increased their price objective on shares of Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a research note on Friday, August 7th. Finally, Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.00.

Insider Buying and Selling at Puma Biotechnology

In other Puma Biotechnology news, Director Alessandra Cesano sold 62,150 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $9.12, for a total transaction of $566,808.00. Following the completion of the transaction, the director directly owned 56,700 shares in the company, valued at $517,104. This represents a 52.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Wilson sold 5,000 shares of Puma Biotechnology stock in a transaction on Monday, September 14th. The shares were sold at an average price of $9.10, for a total value of $45,500.00. Following the transaction, the director directly owned 54,750 shares of the company’s stock, valued at approximately $498,225. The trade was a 8.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 22.20% of the stock is owned by insiders.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s lead product is NERLYNX (neratinib), an oral, irreversible tyrosine kinase inhibitor designed to target HER2 and other members of the epidermal growth factor receptor family.

NERLYNX is approved in the United States for the extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer following adjuvant trastuzumab-based therapy.